Impact of Site-Specific Conjugation of ScFv to Multifunctional Nanomedicines Using Second Generation Maleimide

Archive ouverte

Hervé-Aubert, Katel | Allard-Vannier, Emilie | Joubert, Nicolas | Lakhrif, Zineb | Alric, Christophe | Martin, Camille | Viaud-Massuard, Marie-Claude | Dimier-Poisson, Isabelle | Aubrey, Nicolas | Chourpa, Igor

Edité par CCSD ; American Chemical Society -

International audience. Biocompatible multifunctional nanomedicines (NMs) are known to be an attractive platform for targeted anticancer theranosis. However, these nanomedicines are of interest only if they efficiently target diseased cells and accumulate in tumors. Here we report the synthesis of a new generation of immunotargeted nanomedicines composed of a superparamagnetic iron oxide nanoparticle (SPION) core, polyethylene glycol coating and the anti-HER2 single chain fragment variable (scFv) of Trastuzumab antibody. We developed two novel bioengineered scFv carrying two cysteines located (i) at the end (4D5.1-cys2) or (ii) at the beginning (4D5.2-cys2) of its hexahistidine tag. The scFv bioconjugation was controlled via heterobifunctional linkers including a second generation maleimide (SGM). Our data indicated that the insertion of cysteines at the beginning of the hexahistidine tag was allowed to obtain nearly 2-fold conjugation efficiency (13 scFv/NP) compared to NMs using classical maleimide. As a result, the NMs-4D5.2 built using the optimal 4D5-cys2 and linkers equipped with SGM showed the enhanced recognition of HER2 in an ELISA format and on the surface of SK-BR-3 breast cancer cells in vitro. Their stability in serum was also significantly improved compared to the NMs-4D5. Our results showed the fundamental importance of the controlled ligand conjugation in the perspective of rational design of NMs with tailored physicochemical and biological properties.

Consulter en ligne

Suggestions

Du même auteur

Site-specific conjugation of auristatins onto engineered antibody fragments to target her2-positive breast cancer in vitro

Archive ouverte | Ait Mohamed Amar, Imène | CCSD

poster + "pitch" de présentation du poster de 90sposter + "pitch" de présentation du poster de 90s. The combination of a highly potent cytotoxic agent (drug) with a specific therapeutic monoclonal antibody (mAb) via...

Site-Specific Conjugation of Auristatins onto Engineered scFv Using Second Generation Maleimide to Target HER2-positive Breast Cancer in Vitro

Archive ouverte | Aubrey, Nicolas | CCSD

International audience. Antibody-drug conjugates (ADC) are spearheading vectorized chemotherapy against cancer, with 4 FDA-approved ADCs and 79 in clinical trials. However, most ADCs are produced using a stochastic ...

Multimodal nanovectors with a theranostic potential for cancer treatment

Archive ouverte | Carrouée, Ambre | CCSD

Congrès sous l’égide de la Société Française de Génie Biologique et Médical (SFGBM)Congrès sous l’égide de la Société Française de Génie Biologique et Médical (SFGBM). National audience. Targeted theranosis (diagnos...

Chargement des enrichissements...